IL6 and COVID-19: In a mouse model of ARDS, which is the main cause of death in COVID-19 patients, CD26 inhibition by sitagliptin alleviated histological findings of lung injury by inhibiting the expression of IL-1β, TNF-α, and IL-6[126].